Role of the Fas/FasL Pathway in HIV or SIV Disease by unknown
BioMed CentralRetrovirology
ssOpen AcceReview
Role of the Fas/FasL Pathway in HIV or SIV Disease
Bhawna Poonia, C David Pauza and Maria S Salvato*
Address: Institute of Human Virology, University of Maryland, School of Medicine, 725 W. Lombard Street, Baltimore, MD 21201
Email: Bhawna Poonia - bpoonia@ihv.umaryland.edu; C David Pauza - cdpauza@ihv.umaryland.edu; 
Maria S Salvato* - msalvato@ihv.umaryland.edu
* Corresponding author    
Abstract
Human immunodeficiency virus disease involves progressive destruction of host immunity leading
to opportunistic infections and increased rates for malignancies. Quantitative depletion of immune
cell subsets and accruing defects in cell effector functions are together responsible for
immunodeficiency The broad impact of HIV reflects a similarly broad spectrum of affected cells
including subsets that do not express viral receptors or support viral replication. Indirect cell killing,
the destruction of uninfected cells, is one important mechanism due partly to activation of the Fas/
FasL system for cell death. This death-signaling pathway is induced during HIV disease and
contributes significantly to viral pathogenesis and disease.
Background
Changes in CD4 cell count and viral RNA burden are com-
mon markers for HIV disease progression. However, evi-
dence has existed for several years that many patients with
HIV disease experience a broad loss of leukocyte subsets
without an apparent preference for depleting CD4 T cells
[1-3]. Effects on cell types other than CD4 T cells were
documented in macaques after showing substantial B cell
loss during acute SIV infection [4], and in humans by
showing depletion of γδ T cells [5] that are CD4 negative.
Many other examples confirmed that the profound
impact of HIV on "non-CD4" leukocyte populations
depends on indirect mechanisms, as opposed to direct cell
killing that occurs when HIV or SIV infects and destroys
susceptible CD4+ cells. Surely, uninfected CD4+ cells can
also be destroyed by indirect mechanisms if they escape
direct infection. Since both direct and indirect mecha-
nisms are driven by viral burden, it has been difficult to
distinguish their contributions to CD4+ T cell depletion
and progressing disease. This technical obstacle has
blocked efforts to explore new therapies that target indi-
rect mechanisms for cell depletion in HIV disease.
Besides depleting immune cells, HIV infection is charac-
terized by defects in cell effector functions. Low cytotoxic-
ity among circulating HIV-specific CD8+ T cells has been
attributed to loss of CD3-complex zeta chains [6] and T
cell exhaustion was linked to high levels of PD-1 or CTLA-
4 on the surface of T cells [7,8]. During chronic HIV infec-
tion, immune dysfunction can also result from interac-
tions with regulatory T cells (Tregs) [9,10] that are
exported to the periphery during high thymic turnover
[11]. Ultimately, Tregs contribute to immune suppression
and to cell death via the Fas/FasL apoptotic pathways (Fig.
1).
Mechanisms of indirect cell depletion in HIV infection
Despite overwhelming evidence for indirect cell deple-
tion, little is known about how it occurs in vivo. Cell loss
is accelerated during elevated viremia and a broad recov-
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apy (HAART) [12]. Some of these changes may be related
to release of sequestered lymphocytes from secondary
lymphoid tissues [13] as viral antigen declines during
therapy. HIV effects on bone marrow, thymus, and hemat-
opoietic stem cells were also proposed as causes for gen-
eral leukocyte loss [14]. While HIV does indeed infect and
alter bone marrow and thymus, the kinetics for cell loss
during acute infection, the rates for recovery during
HAART and the durable repertoire defects in T and B cell
subsets after HAART [15,16] argue that these dynamic
changes occur within mature populations without an
overwhelming impact from declining stem cell output.
With large expansions and contractions of mature cell
Major mechanisms of leukocyte cell loss in AIDSFigu e 1
Major mechanisms of leukocyte cell loss in AIDS. Two models for cell death in AIDS are the direct and indirect killing of 
leukocytes during disease progression. Direct killing, or killing of virus-infected cells, is presumed to be virus-mediated or to 
occur via immune surveillance of virus-infected cells, most often by killer T cells. The virus-infected cells are predominately 
memory T cells with the phenotype CD4+CD45RA- or CD4+CD45RA+Fas and are primarily killed by cytotoxic T cells in a 
Fas-independent manner [52]. Indirect cell death, or killing of uninfected "bystander" cells, has also been documented in vivo. All 
leukocytes, including uninfected bystander cells, can be activated, with up-regulation of Fas/FasL and other death mediators, 
after contact with HIV-infected cells or HIV antigens such as soluble tat, gp120, vpr, and nef [20,24,38,39,49]. Thus HIV gene 
expression contributes to both direct and indirect killing mechanisms. Contact with death ligands like FasL causes apoptosis of 
activated cells through Fas/FasL signaling. Tregs are major effectors of bystander killing. The finding that HIV+ cells are less sus-
ceptible to Fas/FasL killing means that HIV+ cells become enriched when Fas-mediated apoptosis is the major death pathway.Page 2 of 8
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on leukocyte depletion in AIDS.
A process described as "chronic immune activation" or
"hyperactivation" occurs during HIV disease and is
accompanied by higher expression of TNF superfamily lig-
ands and their receptors, e. g. Fas/FasL and TRAIL-DR5
[17-20]. Chronic activation coincides with "activation
induced cell death" (AICD), a term coined initially to
describe cell loss occuring when lymphocytes are activated
by viral antigen in the absence of appropriate costimula-
tion. AICD connects viral gene expression to general lym-
phocyte destruction, ultimately resulting in reduced
immune protection from HIV. Now it is known that both
viral and host products can activate lymphocytes and
induce death receptor expression. Secreted HIV Tat pro-
tein up-regulates FasL and TRAIL in T cells or macr-
pophages, which in turn, induce apoptosis in bystander
cells thereby providing a mechanism for cell death among
uninfected cells [21-23]. In HIV disease, both antigen-spe-
cific and polyclonal activation have been observed
[17,24,25]. This pan-activation sensitizes lymphocytes to
apoptotic cell death that occurs when the death ligand,
usually cell-associated, contacts a cell that is expressing
death receptors.
Early investigators [26] proposed apoptotic death as an
important contributor to CD4 T cell depletion. They
observed that triggering through the T cell receptor failed
to induce proliferation of PBMC from HIV+ asympto-
matic donors; instead, CD4 cells in these cultures had fea-
tures consistent with Fas-mediated apoptosis [27]. We
confirmed this result in SIV-infected macaques [28]. Alter-
natively, signaling through the T cell receptor [29] can
activate the mitochondrial pathway for apoptosis, distinct
from the Fas-triggered caspase-8 death pathway [30]. Both
pathways are generally invoked in AICD (Figure 1). Since
antigen-specific memory T cells are more likely to express
Fas, cell killing appears tied to antigen specificity. Both
caspase 8 and mitochondrial apoptosis mechanisms tend
to delete immune cells that respond to antigen. Preferen-
tial apoptotic cell death among antigen-activated T cells
could account for the lack of immune control over oppor-
tunistic pathogens and an insufficiency of viral immunity
that fails to prevent viral persistence or progressing dis-
ease. Once the host environment is "set," and after
viremia triggers higher expression of FasL, every encounter
with antigen has the potential to drive cell depletion
among all lymphocyte compartments.
Role of Fas/FasL mediated cell death in HIV/SIV infections
Apoptosis is observed consistently among uninfected cells
in SIV+ macaques or HIV+ humans [31]. Chronic
immune activation drives cells into apoptosis [32] possi-
bly involving Fas/FasL interactions [33], and reflects an
exaggeration of the normal processes for homeostatic cell
regulation during HIV disease [34]. The roles of assassin
and victim are not always clear in these interactions. Acti-
vated CD4+ T cells can express FasL and become the effec-
tors of cell death including the destruction of resting B
cells [35], even as they also become targets for cell killing
and display high rates for apoptosis during disease.
Many studies have explored the mechanisms connecting
HIV/SIV antigen expression and apoptotic cell death.
Human macrophages express FasL after exposure to HIV
[36], creating a link between antigen presentation and
Fas/FasL-mediated apoptosis. HIV up-regulates FasL in
CD4 T cells [37,38] after they are exposed to soluble Tat,
gp120 [22] or Nef proteins [39]. Higher levels of FasL,
both cell-associated and in plasma, and Fas were observed
in specimens from HIV+ patients whose PBMC were espe-
cially susceptible to Fas-mediated cell death in vitro [40].
Cross-linking of CD4 by gp120 complexes or viral parti-
cles increased the susceptibility to apoptosis triggered by
FasL or TNF-α [41,42].
The patterns of CD4 T cell depletion appear to be antigen-
specific, as perturbation of the CD4 receptor repertoire is
significantly associated with higher plasma viremia [43].
This can be explained by an AICD mechanism or by virus
infection of antigen-activated cells as we proposed [44].
Less data are available to show whether CD8+ T cell or B
cell loss during HIV infection is antigen-specific, although
altered receptor repertoire have been reported in both
cases [45-47]. The γδ T cell population shows a specific
pattern of depletion in HIV disease [5], losing the critical
Vγ2-Jγ1.2+ subset that is required for pathogen and tumor
cell responses but few cells express CD4 and γδ T cells do
not support HIV replication. To the extent that antigen
stimulation is related to cell depletion, AICD may be
invoked as a mechanism for γδ T cell killing. Thus, AICD
is a mechanism that potentially links antigen stimulation
with expression of death ligand receptors, leading to spe-
cific cell depletion.
Neuronal cells that are depleted during chronic HIV infec-
tion comprise an important example of bystander deple-
tion since they are not infected by HIV. Neuronal cell loss
has been attributed to interaction with viral proteins such
as gp120, vpr, nef, and tat, and to soluble neurotoxic fac-
tors released by infected macrophages [48]. The primary
mechanism for neuronal depletion is apoptosis via extrin-
sic Fas-related death receptors or intrinsic mitochondrial
pathways [48]. The fate of neuronal cells during AIDS is
reminiscent of the cell culture studies mentioned previ-
ously that documented apoptotic destruction of unin-
fected cells upon exposure to viral proteins
[20,24,38,39,49].Page 3 of 8
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infection especially implicates the Fas death pathway
since activated T or B cells express Fas. Acute SIV infection
triggers rapid increases in Fas and FasL expression in
peripheral blood [50] as well as in thymus and other lym-
phoid tissues [51]. During acute SIV infection, most T cells
express Fas [52] and there is abundant local expression of
FasL among intestinal lymphocytes [53]. Ablation of
intestinal lamina propria CD4+ cells during SIV infection
can be attributed in part, to the Fas/FasL mediated apop-
totic pathway but it is controversial whether apoptotic
death of uninfected cells exceeds virus-mediated killing of
infected cells. Detailed studies of viral burden and the ris-
ing proportion of SIV+ intestinal T cells argued that direct
depletion of infected cells accounts for the rapid cell loss
[52] without the need to invoke apoptotic killing of unin-
fected cells. These investigators stated that up to 60% of all
memory T cells were infected but that those cells were lost
within 4 days. They defined memory CD4+ cells as those
that were CD45RA- or CD45RA+CD95+, meaning that
Fas+ (CD95+) cells that are highly susceptible to apopto-
sis are included. Circulating lymphocytes and lym-
phocytes from lymph nodes and mucosa were sampled,
but lymphocytes were not sampled from the spleen or
liver, for example, so it is impossible to rule out margina-
tion as an explanation for lymphocyte loss. There is no
way to determine from the experimental design, whether
infected cells are being depleted faster than uninfected
cells.
Another recent publication from Mattapallil's laboratory
notes that early mucosal HIV/SIV infection (2-4 days after
inoculation) demonstrates high levels of infected CD4+
Th-17 T cells that are depleted during the course of infec-
tion [54]. Th-17 cells are proinflammatory effectors of
antiviral immunity and are commonly suppressed by
Treg, most likely being depleted via the Fas pathway. Once
again it is not clear whether depletion is due to cell death
in the category of direct depletion of virus-infected cells or
indirect depletion of uninfected bystander cells. It is
highly improbable that any one mechanism will explain
all events in AIDS pathogenesis, so we expect both mech-
anisms to be operating during infection.
Several important studies have implicated apoptosis
among uninfected cells as a major mechanism for leuko-
cyte depletion. Fas ligation was a probable cause for apop-
tosis in T cells from SIV infected macaques [55]. However,
caspase-independent pathways for T cell apoptosis were
thought to drive cell death in other SIV infection studies
[56]. Cell loss, especially in gut-associated lymphoid tis-
sues, likely occurs by multiple mechanisms and we would
expect depletion of both CD4+ and CD4- cell subsets at
these loci of intense viral replication.
A recent publication described gene expression profiles at
three stages of HIV infection: acute, chronic, and AIDS
[57]. The acute stage had high levels of FasL mRNA expres-
sion that were diminished during the chronic stage. This
observation coincides with earlier published studies
showing a high level of PBMC-susceptibility to AICD dur-
ing the acute stage of SIV infection, and this susceptibility
subsides during the chronic stage [58].
Curiously, infected cells are more resistant to apoptosis
than uninfected cells [23,59]. The apoptosis resistance in
persistently infected lymphoid and monocytic cells was
shown to be independent of active viral production and
involved a modulation of the mitochondrial pathway
[60]. A consequence is that indirect cell killing through
apoptotic mechanisms like Fas/FasL, will destroy acti-
vated, uninfected cells while sparing the fraction of
infected cells. Such a process will tend to increase the pro-
portion of infected cells and diminish the proportion of
uninfected cells in a tissue heavily burdened by SIV or
HIV. Perhaps this mechanism contributes to the very high
proportions of infected cells noted in macaque intestinal
tissues after SIV infection [52] and may help to reconcile
apparent differences between direct and indirect cell
depletion models.
Substantial data have been accumulated on HIV induc-
tion of Fas or FasL, the susceptibility of PBMC from HIV
patients to apoptotic cell death and the reversal of these
conditions by HAART. When viremia was suppressed by
effective HAART, CD4 cells in PBMC had significantly
reduced apoptosis levels that correlated with increasing
CD4 counts in blood even though lymphoid tissue FasL
levels were unchanged [61,62]. Similar findings have been
reported for SIV infections. However, the problem
remains that susceptibility to apoptosis, measured in vitro,
rises and falls with changes in viremia, making it difficult
to separate direct from indirect killing mechanisms in
terms of their relative contributions to disease progres-
sion. In murine systems, these problems are addressed
readily by the use of knock-out mutations eliminating Fas,
FasL or both molecules. For AIDS-related questions, the
initial studies are done most appropriately in nonhuman
primates using SIV or SHIV to establish persistent infec-
tion and then applying interventions to modulate the Fas/
FasL pathway.
Using a recombinant humanized anti-FasL monoclonal
antibody [63] we developed a protocol for treating rhesus
macaques to interrupt the Fas/FasL system. Animals
received a total of 5 injections of anti-FasL given once per
week beginning 2 weeks before SIV-inoculation and fin-
ishing 2 weeks after virus inoculation. The pilot study
showed no effect of anti-FasL on plasma viremia, but
found increased virus-specific immunity and delayed dis-Page 4 of 8
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immunized macaques indicated that anti-FasL treatment
preserved memory T cells, antigen responses after SIV
infection, and was associated with decreased levels of Treg
cells [65]. In the two interventional studies, anti-FasL
delivered before and during the acute infection had a
durable effect on immune status and disease many
months after treatment stopped. These changes were not
reflected in vRNA levels that were similar among treat-
ment and control groups, but were detected in the compo-
sition and activity of other T cell populations. This means
that uninfected effector cells must have been preserved by
the treatment.
Another indication of the importance for indirect cell kill-
ing comes from studies of "naturally-infected" macaques
i.e., sooty mangabeys infected with SIVsmm that maintain
plasma viremia, do not show high susceptibility to in vitro
apoptosis among PBMC and remain disease-free [66].
Here, apoptosis and immune activation were low and ani-
mals did not develop disease despite chronic viremia. The
observation of preserved CD4 T lymphocytes with regen-
erative capacity in spite of high viremia, suggests that virus
alone cannot explain the massive loss of CD4 lym-
phocytes that occurs in pathogenic SIV and HIV infections
[67] and indirect cell killing mechanisms may be impor-
tant.
We reported [68] that half of 56 macaques tested showed
high levels of MHC-unrestricted cytolysis prior to SIV
inoculation and that animals from this group were all
among the rapid progressors. Subsequently, we found
that MHC-unrestricted cytolysis involves the Fas/FasL
pathway [64] and rapid progressors had higher baseline
levels of cell killing through this pathway. In corrobora-
tion of these findings, high levels of lymph node cell
apoptosis during acute SIV infection also predict that ani-
mals will become rapid progressors [69].
Reports showing lower levels of indirect cell killing/apop-
tosis among naturally-infected macaques despite similar
viremia [64,67,70], the correlation between apoptosis
and rapid progression [69] and intervention studies show-
ing disease-sparing after brief treatment with monoclonal
antibody against FasL [64,65] attest to strong relation-
ships between apoptotic killing of uninfected cells and
pathogenesis. The in vitro and tissue studies on HIV agree
with these findings. Disagreements remain about the
mechanisms for cell death, the roles for viral proteins and
the relative importance of Fas versus non-Fas death path-
ways. In addition to direct infection and cell destruction
by viral cytopathic effects or antigen-specific cytotoxicity,
indirect cell killing mechanisms have broad impact on
host immune capacity and are important in the pathogen-
esis of HIV/AIDS.
Significance of indirect cell killing for HIV vaccine/
therapeutics design
Knowing the role for uninfected bystander cell killing in
disease has not resolved the challenge of applying this
information to treating HIV in man. An anti-Fas treatment
during acute infection would be difficult to deliver. Since
it may not modulate vRNA, the main marker for HIV ther-
apy, lengthy studies would be needed to document treat-
ment effects. The use of anti-retroviral therapy during this
time would also obscure the impact of blocking FasL, but
lowering viral burden during the critical time of acute
infection may spare cells from indirect depletion. A com-
bination of anti-FasL plus active immunization during
interrupted HAART is conceivable, but unlikely to be pur-
sued given the treatment choices and durable virus sup-
pression achievable with available drugs. The most likely
application of this knowledge may come in the evaluation
of prophylactic or therapeutic vaccines. If we define viral
proteins that are responsible for inducing bystander cell
killing or identify particular motifs within these proteins
that trigger killing mechanisms, vaccine-elicited antibod-
ies may block these effects and preserve immunity even if
vRNA levels appear unchanged. For example, gp41 pep-
tide was shown to induce NKp44L on CD4+ T cells during
HIV infection, making them highly susceptible to NK
lysis. Immunizing against this peptide reduced ligand
expression on CD4 lymphocytes and decreased apoptosis
rates in SHIV-infected macaques [71] thereby indicating
its role in promoting bystander cell killing. Careful evalu-
ation of cellular apoptosis and tissue levels of Fas or FasL
will be important to evaluate vaccine trials. FasL bearing
CD4 lymphocytes were shown recently to kill antigen
expressing cells following plasmid immunization, result-
ing in both lower antigen expression and subsequent
decreases in antigen-specific cellular immunity [72]. Such
mechanisms may impact other biological therapies in
HIV/AIDS and appropriate inhibitors of Fas/FasL may be
required to properly implement new interventions.
Conclusion
HIV infection depletes a broad profile of leukocyte subsets
including many that do not express CD4 and are not sus-
ceptible to direct virus infection. Models for the loss of
non-CD4+ subsets including activation-induced cell
death, explain the antigen-specific pattern of cell loss and
frequently invoke Fas/FasL interactions as a principal
mediator of cell death. The role for FasL was tested in the
SIV/macaque model for AIDS using recombinant human-
ized monoclonal antibodies to neutralize this cell death
ligand. Treated macaques modulated SIV disease and
increased virus-specific immunity without consistent
reduction in vRNA burden. The status of animals treated
with anti-FasL was similar to natural SIVsmm infection of
sooty mangabeys that have no overt disease despite highPage 5 of 8
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immune hyperactivation.
The Fas/FasL death pathway is an important component
of SIV or HIV disease. Whether this pathway for cell death
is driven by viral proteins, virus particles or induced host
factors remains unknown, although compelling examples
of each exist in literature. The capacity to control activa-
tion of this cell death pathway may be important for the
ultimate success of preventive vaccine strategies. The mag-
nitude and duration of protective immunity, once viral
exposure has occurred, are key to controlling infection
and disease. Cell death pathways like Fas/FasL may be
exploited by HIV to reduce the level of protective immu-
nity and to establish a persistent infection with progress-
ing disease. There is a continuing need to understand
these mechanisms and develop effective interventions to
improve the impact of antiretroviral therapy.
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